$ALNY Tumbles Over 28% on Disappointing Guidance

Alnylam Pharmaceuticals (NASDAQ: ALNY) experienced a sharp decline in its stock value, dropping over 28% following the release of its second-quarter financial results on July 30, 2026. The company announced it had lowered its TTR product sales guidance for the full year by approximately $200 million, citing learnings from its launch in the evolving ATTR-CM market and the normalization of growth after initial patient demand.

### Money Play If Alnylam Pharmaceuticals (NASDAQ: ALNY) investors experienced significant financial losses due to the company's lowered guidance, they may have legal recourse. Investors who purchased securities between November 2025 and May 2026 are encouraged to contact Kessler Topaz Meltzer & Check, LLP.

## Catalyst Analysis: Disappointing Financial Results and Guidance Cut On July 30, 2026, Alnylam Pharmaceuticals reported second-quarter financial results that fell short of expectations, leading to a significant sell-off in its stock. The company explicitly stated a reduction in its full-year 2026 TTR net product revenue guidance by roughly $200 million. This downward revision was attributed to market dynamics and initial launch phase observations within the ATTR-CM market.

## $ALNY+WL Technical Analysis & Key Risk Watch

03.66 · R1 ## $ALNY+WL Technical Analysis & Key Risk Watch 01.74 · last ## $ALNY+WL Technical Analysis & Key Risk Watch 01.65 · S1 ## $ALNY+WL Technical Analysis & Key Risk Watch 01.48 · S2 $99.20.

### Sector Ripple / Impact on Pharmaceuticals The steep decline in Alnylam Pharmaceuticals (NASDAQ: ALNY) may prompt increased scrutiny of other biotechnology firms with similar product lines or market exposure, particularly concerning their own forward-looking sales guidance and execution. Investors will be monitoring other companies for any signs of similar headwinds in the ATTR-CM market or other therapeutic areas.

### Story Arc / How We Got Here This development follows a prior investor alert concerning GPGI, Inc. (GPGI) on August 9, 2026, where a securities fraud class action lawsuit deadline was approaching. While distinct events, both highlight investor vigilance and the potential for legal action when corporate disclosures and market performance diverge significantly, impacting investor recovery options. Prior coverage can be found at /explore/gpgi-faces-securities-fraud-lawsuit-investor-deadline-nears.